Cathay Biotech Inc. (SHA:688065)

Market Cap	35.17B +23.7%
Revenue (ttm)	3.30B +11.4%
Net Income	565.72M +15.7%
EPS	0.83 -1.2%
Shares Out	720.66M
PE Ratio	58.80
Forward PE	41.36
Dividend	0.40 (0.82%)
Ex-Dividend Date	Aug 1, 2025

Volume	3,545,691
Average Volume	5,908,344
Open	48.58
Previous Close	48.41
Day's Range	48.42 - 49.30
52-Week Range	45.00 - 64.50
Beta	0.71
RSI	43.22
Earnings Date	Apr 24, 2026

About Cathay Biotech

Cathay Biotech Inc., together with its subsidiaries, engages in the research, development, production, and sale of bio-based materials in China and internationally. The company offers biological long-chain diacids, including sebacic acid and octadecanedioic acid; bio-based polyamides; and bio-based pentamethylene diamine under the TERRYL and ECOPENT brands. It also provides digital solutions for electrification, automation, and digitization for biological manufacturing. The company’s products are used in textiles, pharmaceuticals, perfumes, aut...

• Industry: Chemicals
• Sector: Materials
• Founded: 2000
• Employees: 1,764
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688065

Financial Performance

In 2025, Cathay Biotech's revenue was 3.30 billion, an increase of 11.41% compared to the previous year's 2.96 billion. Earnings were 565.72 million, an increase of 15.70%.